Researchers from Morphic Therapeutic Inc. and affiliated organizations published data from a study that aimed to assess the potential of using arginylglycylaspartic acid (RGD) integrins for the treatment of cardiovascular diseases, such as pulmonary arterial hypertension (PAH).